Key Points
- CEO Bassil Dahiyat sold 14,870 shares on March 5 at $11.25 for $167,287.50 (leaving him with 552,922 shares, a 2.62% ownership decline); SEC filings show clustered insider sales this week (CEO total 21,476 shares, SVP Celia Eckert 5,011, VP John Desjarlais 6,620), which may be viewed negatively absent disclosed 10b5‑1 plans.
- Xencor reported an EPS beat of ($0.09) versus ($0.64) expected, but revenue dropped 46.6% year-over-year and the company still posts negative margins; analysts hold a consensus "Moderate Buy" with a $25 target.
- Xencor and Genentech ended their protein-therapeutics collaboration, removing a strategic partner and potential milestone/royalty payments while possibly returning program rights to Xencor to pursue independently or with new partners.
Xencor, Inc. (NASDAQ:XNCR - Get Free Report) SVP Celia Eckert sold 1,767 shares of the company's stock in a transaction dated Friday, March 6th. The shares were sold at an average price of $11.02, for a total value of $19,472.34. Following the completion of the sale, the senior vice president owned 76,918 shares of the company's stock, valued at $847,636.36. This represents a 2.25% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Celia Eckert also recently made the following trade(s):
- On Thursday, March 5th, Celia Eckert sold 3,244 shares of Xencor stock. The shares were sold at an average price of $11.25, for a total value of $36,495.00.
- On Tuesday, March 3rd, Celia Eckert sold 1,492 shares of Xencor stock. The stock was sold at an average price of $11.90, for a total value of $17,754.80.
Xencor Price Performance
Xencor stock opened at $11.87 on Tuesday. The company has a current ratio of 6.25, a quick ratio of 6.25 and a debt-to-equity ratio of 0.12. The firm has a market capitalization of $870.55 million, a P/E ratio of -9.57 and a beta of 0.95. The business has a 50-day moving average of $12.73 and a 200-day moving average of $13.03. Xencor, Inc. has a 1 year low of $6.92 and a 1 year high of $18.69.
Xencor (NASDAQ:XNCR - Get Free Report) last announced its quarterly earnings results on Wednesday, February 25th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, beating analysts' consensus estimates of ($0.64) by $0.55. Xencor had a negative net margin of 73.20% and a negative return on equity of 14.58%. The business had revenue of $28.24 million for the quarter, compared to the consensus estimate of $29.97 million. During the same period last year, the company posted ($0.62) EPS. Xencor's revenue for the quarter was down 46.6% on a year-over-year basis. On average, equities analysts anticipate that Xencor, Inc. will post -3.68 EPS for the current year.
Analysts Set New Price Targets
XNCR has been the topic of several analyst reports. Truist Financial assumed coverage on shares of Xencor in a report on Monday, November 24th. They issued a "buy" rating and a $29.00 target price on the stock. Wall Street Zen cut shares of Xencor from a "hold" rating to a "sell" rating in a research report on Saturday, February 28th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Xencor in a research note on Monday, December 29th. Finally, Barclays lifted their target price on Xencor from $26.00 to $27.00 and gave the stock an "overweight" rating in a report on Thursday, February 26th. Eight investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Xencor has a consensus rating of "Moderate Buy" and an average price target of $25.00.
Read Our Latest Stock Analysis on Xencor
Institutional Trading of Xencor
Several hedge funds have recently bought and sold shares of XNCR. Amalgamated Bank lifted its stake in Xencor by 4.8% in the third quarter. Amalgamated Bank now owns 20,846 shares of the biopharmaceutical company's stock valued at $245,000 after buying an additional 947 shares in the last quarter. ProShare Advisors LLC increased its position in shares of Xencor by 6.5% during the fourth quarter. ProShare Advisors LLC now owns 16,853 shares of the biopharmaceutical company's stock worth $258,000 after acquiring an additional 1,026 shares in the last quarter. Cerity Partners LLC increased its position in shares of Xencor by 3.8% during the fourth quarter. Cerity Partners LLC now owns 31,302 shares of the biopharmaceutical company's stock worth $479,000 after acquiring an additional 1,143 shares in the last quarter. HighVista Strategies LLC raised its holdings in shares of Xencor by 4.3% during the second quarter. HighVista Strategies LLC now owns 33,304 shares of the biopharmaceutical company's stock worth $262,000 after acquiring an additional 1,362 shares during the period. Finally, GAMMA Investing LLC raised its holdings in shares of Xencor by 77.1% during the third quarter. GAMMA Investing LLC now owns 3,328 shares of the biopharmaceutical company's stock worth $39,000 after acquiring an additional 1,449 shares during the period.
Key Xencor News
Here are the key news stories impacting Xencor this week:
- Negative Sentiment: Xencor and Genentech have agreed to end their protein-therapeutics collaboration. This removes a strategic partner that could have provided development resources, milestone and/or royalty payments tied to the collaboration and could delay or change the path-to-market for affected programs; however, termination may return rights to Xencor and let the company seek new partners or advance programs independently. Xencor, Genentech to End Protein Therapeutics Collaboration
- Negative Sentiment: Multiple insider sales by senior Xencor executives were disclosed this week: CEO Bassil Dahiyat sold 14,870 shares on March 5 and 6,606 shares on March 6 (total 21,476 shares), SVP Celia Eckert sold 5,011 shares across March 5–6, and VP John Desjarlais sold 6,620 shares across March 5–6. Aggregate proceeds reported are in the low six-figure range per trade. These clustered sales by top executives can be read negatively by the market (profit-taking or reduced insider conviction), unless part of pre-planned 10b5‑1 arrangements (no such plan was disclosed in these notices). Relevant SEC filings: CEO Form 4(s) SVP Form 4(s) VP Form 4(s)
About Xencor
(
Get Free Report)
Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor's research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.
The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
